SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood

Dianna L. Ng, Gregory M. Goldgof, Brian R. Shy, Andrew G. Levine, Joanna Balcerek, Sagar P. Bapat, John Prostko, Mary Rodgers, Kelly Coller, Sandra Pearce, Sergej Franz, Li Du, Mars Stone, Satish K. Pillai, Alicia Sotomayor-Gonzalez, Venice Servellita, Claudia Sanchez San Martin, Andrea Granados, Dustin R. Glasner, Lucy M. Han, Kent Truong, Naomi Akagi, David N. Nguyen, Neil M. Neumann, Daniel Qazi, Elaine Hsu, Wei Gu, Yale A. Santos, Brian Custer, Valerie Green, Phillip Williamson, Nancy K. Hills, Chuanyi M. Lu, Jeffrey D. Whitman, Susan L. Stramer, Candace Wang, Kevin Reyes, Jill M. C. Hakim, Kirk Sujishi, Fariba Alazzeh, Lori Pham, Edward Thornborrow, Ching-Ying Oon, Steve Miller, Theodore Kurtz, Graham Simmons, John Hackett, Michael P. Busch and Charles Y. Chiu ()
Additional contact information
Dianna L. Ng: University of California, San Francisco
Gregory M. Goldgof: University of California, San Francisco
Brian R. Shy: University of California, San Francisco
Andrew G. Levine: University of California, San Francisco
Joanna Balcerek: University of California, San Francisco
Sagar P. Bapat: University of California, San Francisco
John Prostko: Applied Research and Technology, Abbott Diagnostics
Mary Rodgers: Applied Research and Technology, Abbott Diagnostics
Kelly Coller: Applied Research and Technology, Abbott Diagnostics
Sandra Pearce: Applied Research and Technology, Abbott Diagnostics
Sergej Franz: Vitalant Research Institute
Li Du: Vitalant Research Institute
Mars Stone: University of California, San Francisco
Satish K. Pillai: Vitalant Research Institute
Alicia Sotomayor-Gonzalez: University of California, San Francisco
Venice Servellita: University of California, San Francisco
Claudia Sanchez San Martin: University of California, San Francisco
Andrea Granados: University of California, San Francisco
Dustin R. Glasner: University of California, San Francisco
Lucy M. Han: University of California, San Francisco
Kent Truong: University of California, San Francisco
Naomi Akagi: University of California, San Francisco
David N. Nguyen: University of California, San Francisco
Neil M. Neumann: University of California, San Francisco
Daniel Qazi: University of California, San Francisco
Elaine Hsu: University of California, San Francisco
Wei Gu: University of California, San Francisco
Yale A. Santos: University of California, San Francisco
Brian Custer: Vitalant Research Institute
Valerie Green: Creative Testing Solutions
Phillip Williamson: Creative Testing Solutions
Nancy K. Hills: University of California, San Francisco
Chuanyi M. Lu: University of California, San Francisco
Jeffrey D. Whitman: University of California, San Francisco
Susan L. Stramer: American Red Cross
Candace Wang: University of California, San Francisco
Kevin Reyes: University of California, San Francisco
Jill M. C. Hakim: The Division of HIV, ID & Global Medicine
Kirk Sujishi: University of California, San Francisco
Fariba Alazzeh: University of California, San Francisco
Lori Pham: University of California, San Francisco
Edward Thornborrow: University of California, San Francisco
Ching-Ying Oon: University of California, San Francisco
Steve Miller: University of California, San Francisco
Theodore Kurtz: University of California, San Francisco
Graham Simmons: University of California, San Francisco
John Hackett: Applied Research and Technology, Abbott Diagnostics
Michael P. Busch: University of California, San Francisco
Charles Y. Chiu: University of California, San Francisco

Nature Communications, 2020, vol. 11, issue 1, 1-7

Abstract: Abstract Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3–11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-18468-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18468-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-18468-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().